Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Collaboration for Radiotherapy Microphere Drug Development for the Treatment of Primary and Secondary Liver Cancer

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Sirtex Medical, Ltd. (Sydney, Australia) and Guerbet, SA (Villepinte, France) are entering into a clinical studies collaboration in primary and secondary (metastatic) liver cancer.

The aim of the collaboration is to examine how Sirtex’s SIR-Spheres microspheres and Guerbet’s Lipiodol Ultra Fluid may be combined or sequenced optimally—and additionally developed—for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and a variety of other primary and secondary liver cancers.

Sirtex’s chief executive officer, Gilman Wong commented that, “Sirtex’s and Guerbet’s shared vision is that one day, rather than being a terminal disease that patients unfortunately die from, liver cancer may be considered a chronic disease that patients can successfully live with. During my time at Sirtex, I have been fortunate to meet a number of patients who have survived their liver cancer for many years following treatment with SIR-Spheres microspheres. We hope through this clinical studies collaboration to make further gains for the benefit of the patients afflicted by liver cancer. Should the initial collaboration prove fruitful, future collaborations in R&D and marketing between our respective companies may be considered.”

Sirtex’s SIR-Spheres microspheres are utilized in selective internal radiation therapy (SIRT), also known as radioembolization, for the treatment of patients with inoperable liver tumors. SIR-Spheres microspheres have been shown in randomized controlled trials (RCTs) to optimize survival in patients with inoperable liver metastases from primary colorectal cancer. SIR-Spheres microspheres are now being assessed in six international, multicenter RCTs in metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC), which cumulatively will enroll over 2,100 patients. The first of these RCTs, the SIRFLOX study, finished patient enrolment in April 2013 and is expected to report its findings in early 2015.

Guerbet’s Lipiodol Ultra Fluid is used in traditional transarterial chemo-embolization (cTACE) procedures for the treatment of patients with inoperable liver tumors. cTACE has been published in over 100 clinical studies. Recently, cTACE has been established as the standard-of-care for the treatment of patients with intermediate stage HCC by three international clinical consensus guidelines in Europe, Japan, and the United States. These consensus guidelines universally recommend cTACE as the standard-of-care for patients with intermediate stage HCC.

Guerbet’s chief executive officer, Yves L’Epine, said, “We are excited about the potential of combining or sequencing our products to improve the efficacy of interventional radiology procedures in patients with unresectable hepatic tumors. Indeed, while Lipiodol and SIR-Spheres individually are well proven and widely used therapies in their own right, they have never been formally evaluated together or sequentially.”

Guerbet is a pharmaceutical group focused on contrast imaging development, offering of contrast products for X-ray and MRI and for interventional radiology, along with a range of injectors and related medical equipment to provide enhanced diagnosis and treatment of patients.

Related Links:

Sirtex Medical
Guerbet 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.